reason report
break away solid commerci pipelin
line revenu beat signific ep beat versu
consensu lower tighten expens guidanc
revenu beat quarter anticip investor base
collabor partner sanofi disclosur strong antibodi
allianc perform ex-u eylea strength expens
manag posit surpris compani
invest multipl dtc campaign drive revenu
growth key franchis compani cost good
tax rate materi lower expect seem like
sustain base perform quarter
regeneron updat guidanc expect consensu
revenu earn estim increas current
portfolio come week launch dynam dupix
remain strong multipl regulatori clinic event
second half seem pois renew investor excit
franchis expect investor attent pivot away concern
competit risk eylea dupix toward new
revenu opportun includ label expans across age
diseas dupix life-cycle extens strategi eylea
valu assign regeneron immuno-oncolog
strategi excit moder slightli
like impress expens growth come period
support multipl launch signific increment promot
invest base quarterli result manag
comment guidanc increas revenu forecast
pro forma ep estim revenu
forecast consensu higher
higher longer term pro forma ep estim
recent consensu higher
higher longer term base chang
forecast chang peer compani multipl
increas price target reiter
regeneron favor updat element prior guidanc
includ expens tax capit expenditur
compani lower non-gaap unreimburs guidanc
non-gaap sg
tighten updat
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm dilut ep non-gaap
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
estim unreimburs sg
respect conjunct sg chang
regeneron expect total sanofi reimburs commerci
relat expens prior regeneron
also expect effect tax rate rang compar
prior reduct regeneron intern expens
lower tax rate view posit investor
time frustrat compani opaqu report limit
cash flow convers continu massiv invest
sg facil
previous cover highlight regeneron
confer call recap note link
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani come initi base portfolio fast-
follow second entrant rapidli grow biopharmaceut market first product eylea
continu surpris investor taken grown market intraocular
vegf vascular endotheli growth factor antibodi treatment eylea contribut nearli
global sale trump categori pioneer roch lucenti well
cheaper altern compound bevacizumab remain posit eylea expect
continu grow lose market share emerg competitor
novarti seem like approv excit aspect
compani next wave innov antibodi notabl dupix approv
adult atop dermat like receiv label expans multipl allerg diseas
indic expect dupix dupilumab gener revenu
signific upsid indic longer term regeneron wholli own
antibodi could contribut meaning revenu earn growth
period current compani invest mode result earn cash flow
convers revenu lag peer industri anticip cash flow true
earn improv period profit antibodi collabor
sanofi begin accumul
revenu in-lin us eylea sale despit small inventori headwind
higher discount regeneron report global eylea sale consensu
line number us sale eylea line consensu
estim regeneron disclos small inventori
decreas level normal week rang howev headwind
magnifi higher discount offer physician practic regardless
volum eylea use strategi allow regeneron compet roch anti-
vegf class clean contract practic headwind continu
call regeneron also disclos intern survey demonstr us
eylea sale wet-amd dme dme indic remain less
penetr increas market penetr compani plan increas
commerci invest diabet eye diseas start dtc campaign dme
ex-u eylea sale consensu estim
estim net currenc period year ago
result sanofi collabor product previous disclos last friday sanofi
varianc consensu estim alreadi anticip market
global praluent sale dupix sale
consensu estim partner sanofi report total collabor revenu
regeneron partnership sanofi bayer teva teva quarter
line consensu estim reflect strength ex-u eylea
profit share higher reimburs sg expens
lower expens tax rate drove magnifi ep regeneron report total non-
oper expens consensu
estim surpris balanc cog
consensu respect gross margin quarter
impress increas compani already-stellar gross margin last
year quarter manag attribut quarter increas less product spoilag
usual initi impact leverag overhead expens limerick ireland
manufactur facil product includ sanofi allianc record cog
allianc level gross margin may remain near level futur quarter expect
expens increas significantli regeneron increas market invest eylea
dupix continu recruit increasingli larg costli immuno-oncolog trial
regeneron also report lower tax rate compar consensu forecast
combin expens manag help deriv pro forma ep
yoy consensu estim
eylea line extens track competit challeng still lack advantag
though eylea oldest product regeneron compani final recogn valu
import line extens durabl overal valu franchis
compani multipl signific enhanc underway
rais bar entri commerci rotat array two-year-away
competitor first compani supplement biolog licens applic sbla everi
week treatment wet-amd current fda review pdufa date august
compani submit sbla treatment nonprolif diabet retinopathi
npdr quarter result approv signific new indic
later year regeneron report one-year data phase panorama studi
support npdr sbla regeneron also submit sbla pre-fil syring
version eylea product improv alreadi util roch lucenti
well-receiv market final regeneron announc higher-dos formul
eylea preclin develop could enter clinic potenti either increas
efficaci extend dose interv comparison forthcom competitor
less stellar data unaccept rate ocular inflamm
allergan abicipar see note link roch disclos dose-depend safeti risk
gastrointestin disord procedur complic nervou system disord
lucenti port deliveri advers event rate inject lucenti
multipl dupix clinic regulatori event scatter month
next month regeneron expect us fda decis sbla asthma
adult/adolesc patient pdufa date octob submit sbla
market author applic expand atop dermat indic
adolesc patient year age compani expect report phase data
nasal polyp program year initi new pivot trial eosinophil esophag
eoe proof concept trial peanut allergi season allergi chronic obstruct
upcom cemiplimab approv put oncolog strategi focu one regeneron
import catalyst approv antibodi cemiplimab cutan squamou
cell carcinoma cscc cancer current approv immuno-oncolog
agent regeneron drug slate first diseas compani pdufa date
octob anticip earlier approv base approv histori checkpoint
inhibitor class new cancer indic regeneron appear prepar earli approv
well confirm commerci organ place product inventori avail
launch immedi regeneron late-stag clinic focu front-lin
non-smal cell lung cancer nsclc compani enrol front-lin monotherapi trial
standard-of-car chemotherapi data report late-stag trial
smaller commerci opportun also on-going ovarian cancer basal cell carcinoma
model updat increas revenu ep pt follow
result guidanc revis revenu earn forecast better reflect
compani outlook decreas us eylea forecast rais forecast ex-
us sale regeneron share profit given strong
sequenti growth momentum increas revenu estim dupix
due strength quarter left futur year unchang materi
updat forecast collabor revenu sanofi increas
base plan commerci spend reimburs
regeneron chang increas revenu forecast regeneron next
year materi consensu increas gross margin
forecast decreas oper expens lower tax rate result
pro forma ep forecast increas period
consensu pro forma ep estim
base chang
revenu earn forecast chang relev peer compani multipl
adjust price target reiter outperform rate stock
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag larg cap larg molecul therapeut compani nvo
nv earn multipl ep appli current ep estim
give valu use high growth revenu multipl similar compani
nvo consensu sale appli
revenu estim give valu lastli dcf valuat given
wacc termin cash flow growth rate give present valu averag
three method current price target
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand compani cholesterol treatment praluent subsequ releas
cardiovascular outcom data regeneron fail match cardiovascular outcom
demonstr rival product would advers affect
revenu outlook valuat lastli compani convert rel littl
revenu cash flow today histori return cash investor ultim
may undermin valu stock investor willing continu
sale
collabor
share count period dilut mm
guidanc
tax non-gaap pre-tax incom
sanofi reimburs regeneron
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time event
fda approv dose interv
fda approv use apheresi
fda approv adult/adolesc patient
sbla submiss adolesc patient
year age
one-year data phase panorama
phase efficaci result osteoarthr pain
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
praluent outcom
eylea dr w/o dme
nsclc basal cell
million
leerink partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink partner target regeneron
method high growth larg cap growth biotech ep multipl
ep nvo nv
leerink partner forma ep estim
impli price ep
equiti
number period
method larg cap biopharma forward multipl enu
discount
larg cap high growth biopharma price/sal multipl
leerink partner revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
leerink partner research compani file factset
